Citigroup
VIR icon

Citigroup’s Vir Biotechnology VIR Stock Holding History

Citigroup’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-38,700
Closed -$284K – 5997
2024
Q4 		$284K Buy
+38,700
New +$305K ﹤0.01% 4183
2023
Q1 		– Sell
-29,900
Closed -$757K – 5889
2022
Q4 		$757K Buy
+29,900
New +$733K ﹤0.01% 2867

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Citigroup's VIR Position: Q1 2026 in Review

Citigroup reduced its Vir Biotechnology (VIR) stake by 18% in Q1 2026, selling an estimated $439K and leaving 256,140 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2585.

Citigroup first reported a position in VIR in Q4 2019 and has held it in 26 quarters since. The position peaked at $11.4M in Q1 2024. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Citigroup held 256,140 shares of Vir Biotechnology worth $2.3M as of Q1 2026.
  • Citigroup sold 55,147 Vir Biotechnology shares in Q1 2026, an estimated $439K.
  • Vir Biotechnology made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2585 holding.
  • Citigroup first reported a position in Vir Biotechnology in Q4 2019 and has held it in 26 quarters since.
  • Citigroup's Vir Biotechnology position peaked at $11.4M in Q1 2024.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.